Sustained drug delivery platform may eliminate daily administration

CHICAGO – At the Ophthalmology Innovation Summit here, Robert Butchofsky, founder and CEO of Mati Therapeutics, discusses the investigational drug delivery platform aimed to treat various ocular diseases, including glaucoma using punctal plugs as an anchoring device to deliver drugs to the tear film of the eye. The lead product is completing phase 2 trials using latanoprost with plans to start phase 3 in 2015.